How To Develop A Patient-First Strategy For CGT Commercialization
A patient centric approach to a complex treatment journey
Executive Summary
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.
You may also be interested in...
The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs
As big pharma braces for a new wave of patent expiries, we speak to two former industry chiefs – Novartis’s Joe Jimenez and Schering-Plough’s Fred Hassan – about the approach they took in similar circumstances.
Where Are The Women? Nordic Biotech Searches For The ‘She-Suite’
For all its good intentions and lauded action toward gender equality, the biotech industry in Scandinavia and the Nordics has a female CEO rate hovering around 23%. While the number of women entering academia, innovative companies and laboratories is healthy, gender equality in the C-suite leaves a lot to be desired.
Where Are The Women? Nordic Biotech Searches For The ‘She-Suite’
For all its good intentions and lauded action toward gender equality, the biotech industry in Scandinavia and the Nordics has a female CEO rate hovering around 23%. While the number of women entering academia, innovative companies and laboratories is healthy, gender equality in the C-suite leaves a lot to be desired.